Engineered nanoparticles. How brain friendly is this new guest?

Progress in Neurobiology

Volumn 119-120, Issue , 2014, Pages 20-38

  Cupaioli, Francesca A ^a   Zucca, Fabio A ^a   Boraschi, Diana ^b   Zecca, Luigi ^a  

^a INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

^b CNR   (Italy)

Author keywords

Blood brain barrier; Brain; Nanoparticle; Neurodegeneration; Neuroinflammation; Neurotoxicity

Indexed keywords

LIPOSOME; NANOPARTICLE; POLYMER; PROTEIN BAX; QUANTUM DOT; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; AIR POLLUTANT;

AIR POLLUTION; APOPTOSIS; AUTOPHAGY; BLOOD BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM; CYTOSKELETON; DRUG DELIVERY SYSTEM; ENCEPHALITIS; GLIA CELL; HEALTH HAZARD; HUMAN; LIPOSOMAL DELIVERY; MICROGLIA; NANOENGINEERING; NERVE CELL; NERVE DEGENERATION; NERVE ENDING; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NEUROTOXICITY; NEUROTOXICOLOGY; NONHUMAN; PHYSICAL CHEMISTRY; PLURIPOTENT STEM CELL; POLYMERIZATION; PRIORITY JOURNAL; RESPIRATORY CHAIN; RESPIRATORY EPITHELIUM; REVIEW; AIR POLLUTANT; ANIMAL; CHEMISTRY; DIAGNOSTIC USE; IMMUNOLOGY; METABOLISM;

AIR POLLUTANTS; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES;

EID: 84905393725     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2014.05.002     Document Type: Review

References (205)

1. Abbott N.J., Rönnbäck L., Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 2006, 7:41-53.
2. Adams M.L., Lavasanifar A., Kwon G.S. Amphiphilic block copolymers for drug delivery. J. Pharm. Sci. 2003, 92:1343-1355.
3. Amato I. Making the right stuff. Sci. News 1989, 136:108-110.
4. Andersen A.J., Windschiegl B., Ilbasmis-Tamer S., Degim I.T., Hunter A.C., Andresen T.L., Moghimi S.M. Complement activation by PEG-functionalized multi-walled carbon nanotubes is independent of PEG molecular mass and surface density. Nanomedicine 2013, 9:469-473.
5. Andrieux K., Couvreur P. Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the blood-brain barrier. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2009, 1:463-474.
6. Armulik A., Genové G., Mäe M., Nisancioglu M.H., Wallgard E., Niaudet C., He L., Norlin J., Lindblom P., Strittmatter K., Johansson B.R., Betsholtz C. Pericytes regulate the blood-brain barrier. Nature 2010, 468:557-561.
7. Artzner F., Zantl R., Rädler J. Lipid-DNA and lipid-polyelectrolyte mesophases: structure and exchange kinetics. Cell. Mol. Biol. (Noisy-le-grand) 2000, 46:967-978.
8. AshaRani P.V., Low Kah Mun G., Hande M.P., Valiyaveettil S. Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS Nano 2009, 3:279-290.
9. Au C., Mutkus L., Dobson A., Riffle J., Lalli J., Aschner M. Effects of nanoparticles on the adhesion and cell viability on astrocytes. Biol. Trace Elem. Res. 2007, 120:248-256.
10. Bailey R.E., Smith M.A., Nie S. Quantum dots in biology and medicine. Phys. E: Low-dimens. Syst. Nanostruct. 2004, 25:1-12.
11. Balasubramanian S.K., Jittiwat J., Manikandan J., Ong C.N., Yu L.E., Ong W.Y. Biodistribution of gold nanoparticles and gene expression changes in the liver and spleen after intravenous administration in rats. Biomaterials 2010, 31:2034-2042.
12. Balasubramanian S.K., Poh K.W., Ong C.N., Kreyling W.G., Ong W.Y., Yu L.E. The effect of primary particle size on biodistribution of inhaled gold nano-agglomerates. Biomaterials 2013, 34:5439-5452.
13. Barratt G.M. Therapeutic applications of colloidal drug carriers. Pharm. Sci. Technol. Today 2000, 3:163-171.
14. Bawarski W.E., Chidlowsky E., Bharali D.J., Mousa S.A. Emerging nanopharmaceuticals. Nanomedicine 2008, 4:273-282.
15. Bazile D.V., Ropert C., Huve P., Verrecchia T., Marlard M., Frydman A., Veillard M., Spenlehauer G. Body distribution of fully biodegradable [14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials 1992, 13:1093-1102.
16. Bernardi A., Frozza R.L., Hoppe J.B., Salbego C., Pohlmann A.R., Battastini A.M., Guterres S.S. The antiproliferative effect of indomethacin-loaded lipid-core nanocapsules in glioma cells is mediated by cell cycle regulation, differentiation, and the inhibition of survival pathways. Int. J. Nanomed. 2013, 8:711-728.
17. Bertin A., Steibel J., Michou-Gallani A.I., Gallani J.L., Felder-Flesch D. Development of a dendritic manganese-enhanced magnetic resonance imaging (MEMRI) contrast agent: synthesis, toxicity (in vitro) and relaxivity (in vitro, in vivo) studies. Bioconjug. Chem. 2009, 20:760-767.
18. Biswas S., Dodwadkar N.S., Sawant R.R., Koshkaryev A., Torchilin V.P. Surface modification of liposomes with rhodamine-123-conjugated polymer results in enhanced mitochondrial targeting. J. Drug Target. 2011, 19:552-561.
19. Blasi P., Giovagnoli S., Schoubben A., Ricci M., Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv. Drug Deliv. Rev. 2007, 59:454-477.
20. Block M.L., Calderón-Garcidueñas L. Air pollution: mechanisms of neuroinflammation and CNS disease. Trends Neurosci. 2009, 32:506-516.
21. Block M.L., Elder A., Auten R.L., Bilbo S.D., Chen H., Chen J.C., Cory-Slechta D.A., Costa D., Diaz-Sanchez D., Dorman D.C., Gold D.R., Gray K., Jeng H.A., Kaufman J.D., Kleinman M.T., Kirshner A., Lawler C., Miller D.S., Nadadur S.S., Ritz B., Semmens E.O., Tonelli L.H., Veronesi B., Wright R.O., Wright R.J. The outdoor air pollution and brain health workshop. Neurotoxicology 2012, 33:972-984.
22. Bondarenko O., Juganson K., Ivask A., Kasemets K., Mortimer M., Kahru A. Toxicity of Ag, CuO and ZnO nanoparticles to selected environmentally relevant test organisms and mammalian cells in vitro: a critical review. Arch. Toxicol. 2013, 87:1181-1200.
23. Bondì M.L., Craparo E.F. Solid lipid nanoparticles for applications in gene therapy: a review of the state of the art. Expert Opin. Drug Deliv. 2010, 7:7-18.
24. Bonner J.C., Silva R.M., Taylor A.J., Brown J.M., Hilderbrand S.C., Castranova V., Porter D., Elder A., Oberdörster G., Harkema J.R., Bramble L.A., Kavanagh T.J., Botta D., Nel A., Pinkerton K.E. Interlaboratory evaluation of rodent pulmonary responses to engineered nanomaterials: the NIEHS nano GO consortium. Environ. Health Perspect. 2013, 121:676-682.
25. Boraschi D., Lucchesi D., Hainzl S., Leitner M., Maier E., Mangelberger D., Oostingh G.J., Pfaller T., Pixner C., Posselt G., Italiani P., Nold M.F., Nold-Petry C.A., Bufler P., Dinarello C.A. IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur. Cytokine Netw. 2011, 22:127-147.
26. Borm P.J.A., Robbins D., Haubold S., Kuhlbusch T., Fissan H., Donaldson K., Schins R., Stone V., Kreyling W., Lademann J., Krutmann J., Warheit D., Oberdorster E. The potential risks of nanomaterials: a review carried out for ECETOC. Part. Fibre Toxicol. 2006, 3:11.
27. Brasnjevic I., Steinbusch H.W., Schmitz C., Martinez-Martinez P. Delivery of peptide and protein drugs over the blood-brain barrier. Prog. Neurobiol. 2009, 87:212-251.
28. Calderón-Garcidueñas L., Maronpot R.R., Torres-Jardon R., Henríquez-Roldán C., Schoonhoven R., Acuña-Ayala H., Villarreal-Calderón A., Nakamura J., Fernando R., Reed W., Azzarelli B., Swenberg J.A. DNA damage in nasal and brain tissues of canines exposed to air pollutants is associated with evidence of chronic brain inflammation and neurodegeneration. Toxicol. Pathol. 2003, 31:524-538.
29. Calderón-Garcidueñas L., Azzarelli B., Acuna H., Garcia R., Gambling T.M., Osnaya N., Monroy S., Del Tizapantzi M.R., Carson J.L., Villarreal-Calderon A., Rewcastle B. Air pollution and brain damage. Toxicol. Pathol. 2002, 30:373-389.
30. Casals E., Pfaller T., Duschl A., Oostingh G.J., Puntes V. Time evolution of the nanoparticle protein corona. ACS Nano 2010, 4:3623-3632.
31. Caracciolo G., Amenitsch H. Cationic liposome/DNA complexes: from structure to interactions with cellular membranes. Eur. Biophys. J. 2012, 41:815-829.
32. Cengelli F., Voinesco F., Juillerat-Jeanneret L. Interaction of cationic ultrasmall superparamagnetic iron oxide nanoparticles with human melanoma cells. Nanomedicine (Lond.) 2010, 5:1075-1087.
33. Chan W.C., Maxwell D.J., Gao X., Bailey R.E., Han M., Nie S. Luminescent quantum dots for multiplexed biological detection and imaging. Curr. Opin. Biotechnol. 2002, 13:40-46.
34. Chang J., Jallouli Y., Kroubi M., Yuan X., Feng W., Kang C., Pu P., Betbeder D. Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. Int. J. Pharm. 2009, 379:285-292.
35. Chen L., Yokel R.A., Hennig B., Toborek M. Manufactured aluminum oxide nanoparticles decrease expression of tight junction proteins in brain vasculature. J. Neuroimmune Pharmacol. 2008, 3:286-295.
36. Chen Y., Liu L. Modern methods for delivery of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev. 2012, 64:640-665.
37. Chen Y.S., Hung Y.C., Lin L.W., Liau I., Hong M.Y., Huang G.S. Size-dependent impairment of cognition in mice caused by the injection of gold nanoparticles. Nanotechnology 2010, 21:485102.
38. Cheng Y., Zhao L., Li Y., Xu T. Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives. Chem. Soc. Rev. 2011, 40:2673-2703.
39. Choi J., Zheng Q., Katz H.E., Guilarte T.R. Silica-based nanoparticle uptake and cellular response by primary microglia. Environ. Health Perspect. 2010, 118:589-595.
40. Costa C.S., Ronconi J.V., Daufenbach J.F., Gonçalves C.L., Rezin G.T., Streck E.L., Paula M.M. In vitro effects of silver nanoparticles on the mitochondrial respiratory chain. Mol. Cell. Biochem. 2010, 342:51-56.
41. Costantino L. Drug delivery to the CNS and polymeric nanoparticulate carriers. Future Med. Chem. 2010, 2:1681-1701.
42. Costantino L., Boraschi D. Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents?. Drug Discov. Today 2012, 17:367-378.
43. Couvreur P., Dubernet C., Puisieux F. Controlled drug delivery with nanoparticles: current possibilities and future trends. Eur. J. Pharm. Biopharm. 1995, 41:2-13.
44. Crane R.A., Dickinson M., Popescu I.C., Scott T.B. Magnetite and zero-valent iron nanoparticles for the remediation of uranium contaminated environmental water. Water Res. 2011, 45:2931-2942.
45. da Silveira E.F., Chassot J.M., Teixeira F.C., Azambuja J.H., Debom G., Beira F.T., Del Pino F.A., Lourenço A., Horn A.P., Cruz L., Spanevello R.M., Braganhol E. Ketoprofen-loaded polymeric nanocapsules selectively inhibit cancer cell growth in vitro and in preclinical model of glioblastoma multiforme. Invest. New Drugs 2013, 31:1424-1435.
46. Damm C., Münstedt H., Rosch A. The antimicrobial efficacy of polyamide 6/silver-nano- and microcomposites. Mater. Chem. Phys. 2008, 108:61-66.
47. Danscher G., Locht L.J. In vivo liberation of silver ions from metallic silver surfaces. Histochem. Cell. Biol. 2010, 133:359-366.
48. Davis M.M. A prescription for human immunology. Immunity 2008, 29:835-838.
49. Decuzzi P., Godin B., Tanaka T., Lee S.Y., Chiappini C., Liu X., Ferrari M. Size and shape effects in the biodistribution of intravascularly injected particles. J. Control. Release 2010, 141:320-327.
50. Demento S.L., Eisenbarth S.C., Foellmer H.G., Platt C., Caplan M.J., Mark Saltzman W., Mellman I., Ledizet M., Fikrig E., Flavell R.A., Fahmy T.M. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 2009, 27:3013-3021.
51. Desai A., Vyas T., Amiji M. Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations. J. Pharm. Sci. 2008, 97:2745-2756.
52. Dhanikula R.S., Hammady T., Hildgen P. On the mechanism and dynamics of uptake and permeation of polyether-copolyester dendrimers across an in vitro blood-brain barrier model. J. Pharm. Sci. 2009, 98:3748-3760.
53. Dobson J. Nanoscale biogenic iron oxides and neurodegenerative disease. FEBS Lett. 2001, 496:1-5.
54. Dorman D.C., Struve M.F., Wong B.A., Dye J.A., Robertson I.D. Correlation of brain magnetic resonance imaging changes with pallidal manganese concentrations in rhesus monkeys following subchronic manganese inhalation. Toxicol. Sci. 2006, 92:219-227.
55. Du Y., Luna L.E., Siew Tan W., Rubner M.F., Cohen R.E. Hollow silica nanoparticles in UV-visible antireflection coatings for poly(methyl methacrylate) substrates. ACS Nano 2010, 4:4308-4316.
56. Duncan T.V. Applications of nanotechnology in food packaging and food safety: barrier, materials, antimicrobicals and sensors. J. Colloid Interface Sci. 2011, 363:1-24.
57. Etheridge M.L., Campbell S.A., Erdman A.G., Haynes C.L., Wolf S.M., McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine 2013, 9:1-14.
58. Fang J.H., Lai Y.H., Chiu T.L., Chen Y.Y., Hu S.H., Chen S.Y. Magnetic core-shell nanocapsules with dual-targeting capabilities and co-delivery of multiple drugs to treat brain gliomas. Adv. Healthcare Mater. 2014, (Epub ahead of print). 10.1002/adhm.201300598.
59. Fenart L., Casanova A., Dehouck B., Duhem C., Slupek S., Cecchelli R., Betbeder D. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J. Pharmacol. Exp. Ther. 1999, 291:1017-1022.
60. Fernandes C., Soni U., Patravale V. Nano-interventions for neurodegenerative disorders. Pharmacol. Res. 2010, 62:166-178.
61. Feynman R.P. There's plenty of room at the bottom: an invitation to enter a new field of physics. Eng. Sci. 1960, 23:22-36.
62. Fuciños C., Guerra N.P., Teijón J.M., Pastrana L.M., Rúa M.L., Katime I. Use of poly(N-isopropylacrylamide) nanohydrogels for the controlled release of pimaricin in active packaging. J. Food Sci. 2012, 77:N21-N28.
63. Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 2003, 42:419-436.
64. Gabizon A.A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 2001, 19:424-436.
65. Garcia-Garcia E., Andrieux K., Gil S., Couvreur P. Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain?. Int. J. Pharm. 2005, 298:274-292.
66. Geldenhuys W., Wehrung D., Groshev A., Hirani A., Sutariya V. Brain-targeted delivery of doxorubicin using glutathione-coated nanoparticles for brain cancers. Pharm. Dev. Technol. 2014, (Epub ahead of print).
67. Gheshlaghi Z.N., Riazi G.H., Ahmadian S., Ghafari M., Mahinpour R. Toxicity and interaction of titanium dioxide nanoparticles with microtubule protein. Acta. Biochim. Biophys. Sin. (Shanghai) 2008, 40:777-782.
68. Gramowski A., Flossdorf J., Bhattacharya K., Jonas L., Lantow M., Rahman Q., Schiffmann D., Weiss D.G., Dopp E. Nanoparticles induce changes of the electrical activity of neuronal networks on microelectrode array neurochips. Environ. Health Perspect. 2010, 118:1363-1369.
69. Gross O., Thomas C.J., Guarda G., Tschopp J. The inflammasome: an integrated view. Immunol. Rev. 2011, 243:136-151.
70. Gu J., Xu H., Han Y., Dai W., Hao W., Wang C., Gu N., Xu H., Cao J. The internalization pathway, metabolic fate and biological effect of superparamagnetic iron oxide nanoparticles in the macrophage-like RAW264.7 cell. Sci. China Life Sci. 2011, 54:793-805.
71. Guo D., Xie G., Luo J. Mechanical properties of nanoparticles: basics and applications. J. Phys. D: Appl. Phys. 2014, 47:013001.
72. Hajipour M.J., Fromm K.M., Ashkarran A.A., Jimenez de Aberasturi D., de Larramendi I.R., Rojo T., Serpooshan V., Parak W.J., Mahmoudi M. Antibacterial properties of nanoparticles. Trends Biotechnol. 2012, 30:499-511. Erratum in: Trends Biotechnol. 2013 January; 31 (1): 61-62.
73. Halamoda Kenzaoui B., Chapuis Bernasconi C., Guney-Ayra S., Juillerat-Jeanneret L. Induction of oxidative stress, lysosome activation and autophagy by nanoparticles in human brain-derived endothelial cells. Biochem. J. 2012, 441:813-821.
74. Hamilton J.A., Brunaldi K. A model for fatty acid transport into the brain. J. Mol. Neurosci. 2007, 33:12-17.
75. Han L., Li J., Huang S., Huang R., Liu S., Hu X., Yi P., Shan D., Wang X., Lei H., Jiang C. Peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-targeted T1 magnetic resonance imaging contrast agent. Biomaterials 2011, 32:2989-2998.
76. Hans M.L., Lowman A.M. Biodegradable nanoparticles for drug delivery and targeting. Curr. Opin. Solid State Mater. Sci. 2002, 6:319-327.
77. Hautot D., Pankhurst Q.A., Khan N., Dobson J. Preliminary evaluation of nanoscale biogenic magnetite in Alzheimer's disease brain tissue. Proc. Biol. Sci. 2003, 270(Suppl. 1):S62-S64.
78. Hervé F., Ghinea N., Scherrmann J.M. CNS delivery via adsorptive transcytosis. AAPS J. 2008, 10:455-472.
79. Hildebrandt N., Geissler D. Semiconductor quantum dots as FRET acceptors for multiplexed diagnostics and molecular ruler application. Adv. Exp. Med. Biol. 2012, 733:75-86.
80. Hofmann-Amtenbrink M., Hofmann H., Montet X. Superparamagnetic nanoparticles - a tool for early diagnostics. Swiss Med. Wkly. 2010, 140:w13081.
81. Hougeir F.G., Kircik L. A review of delivery systems in cosmetics. Dermatol. Ther. 2012, 25:234-237.
82. Hsin Y.H., Chen C.F., Huang S., Shih T.S., Lai P.S., Chueh P.J. The apoptotic effect of nanosilver is mediated by a ROS- and JNK-dependent mechanism involving the mitochondrial pathway in NIH3T3 cells. Toxicol. Lett. 2008, 179:130-139.
83. Hussain S.M., Javorina A.K., Schrand A.M., Duhart H.M., Ali S.F., Schlager J.J. The interaction of manganese nanoparticles with PC-12 cells induces dopamine depletion. Toxicol. Sci. 2006, 92:456-463.
84. Hutter E., Boridy S., Labrecque S., Lalancette-Hébert M., Kriz J., Winnik F.M., Maysinger D. Microglial response to gold nanoparticles. ACS Nano 2010, 4:2595-2606.
85. Huynh N.T., Passirani C., Saulnier P., Benoit J.P. Lipid nanocapsules: a new platform for nanomedicine. Int. J. Pharm. 2009, 379:201-209.
86. Jiang J., Oberdörster G., Elder A., Gelein R., Mercer P., Biswas P. Does nanoparticle activity depend upon size and crystal phase?. Nanotoxicology 2008, 2:33-42.
87. Koshkaryev A., Thekkedath R., Pagano C., Meerovich I., Torchilin V.P. Targeting of lysosomes by liposomes modified with octadecyl-rhodamine B. J. Drug Target. 2011, 19:606-614.
88. Kreuter J. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J. Nanosci. Nanotechnol. 2004, 4:484-488.
89. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 2001, 47:65-81.
90. Kreuter J. Drug targeting with nanoparticles. Eur. J. Drug Metab. Pharmacokinet. 1994, 19:253-256.
91. Kreuter J., Alyautdin R.N., Kharkevich D.A., Ivanov A.A. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 1995, 674:171-174.
92. Kreuter J., Petrov V.E., Kharkevich D.A., Alyautdin R.N. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J. Control. Release 1997, 49:81-87.
93. Kreuter J., Ramge P., Petrov V., Hamm S., Gelperina S.E., Engelhardt B., Alyautdin R., von Briesen H., Begley D.J. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res. 2003, 20:409-416.
94. Kreuter J., Shamenkov D., Petrov V., Ramge P., Cychutek K., Koch-Brandt C., Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target. 2002, 10:317-325.
95. Kuznetsov A.V. Modelling transport of layered double hydroxide nanoparticles in axons and dendrites of cortical neurons. Comput. Methods Biomech. Biomed. Eng. 2011, 20:1-9.
96. Lafuente J.V., Sharma A., Patnaik R., Muresanu D.F., Sharma H.S. Diabetes exacerbates nanoparticles induced brain pathology. CNS Neurol. Disord. Drug Targets 2012, 11:26-39.
97. Lansdown A.B. Critical observations on the neurotoxicity of silver. Crit. Rev. Toxicol. 2007, 37:237-250.
98. Letchford K., Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur. J. Pharm. Biopharm. 2007, 65:259-269.
99. Levesque S., Surace M.J., McDonald J., Block M.L. Air pollution & the brain: subchronic diesel exhaust exposure causes neuroinflammation and elevates early markers of neurodegenerative disease. J. Neuroinflamm. 2011, 8:105.
100. Levesque S., Taetzsch T., Lull M.E., Kodavanti U., Stadler K., Wagner A., Johnson J.A., Duke L., Kodavanti P., Surace M.J., Block M.L. Diesel exhaust activates and primes microglia: air pollution, neuroinflammation, and regulation of dopaminergic neurotoxicity. Environ. Health Perspect. 2011, 119:1149-1155.
101. Li J.J., Hartono D., Ong C.N., Bay B.H., Yung L.Y. Autophagy and oxidative stress associated with gold nanoparticles. Biomaterials 2010, 31:5996-6003.
102. Li S. Hydrolytic degradation characteristics of aliphatic polyesters derived from lactic and glycolic acids. J. Biomed. Mater. Res. 1999, 48:342-353.
103. Li S.D., Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim. Biophys. Acta 2009, 1788:2259-2266.
104. Li X.B., Zheng H., Zhang Z.R., Li M., Huang Z.Y., Schluesener H.J., Li Y.Y., Xu S.Q. Glia activation induced by peripheral administration of aluminum oxide nanoparticles in rat brains. Nanomedicine 2009, 5:473-479.
105. Li C., Wang S., Zhang Q., Jia D. Evaluation of minimum quantity lubrication grinding with nano-particles and recent related patents. Recent Pat. Nanotechnol. 2013, 7:167-181.
106. Limbach L.K., Li Y., Grass R.N., Brunner T.J., Hintermann M.A., Muller M., Gunther D., Stark W.J. Oxide nanoparticle uptake in human lung fibroblasts: effects of particle size, agglomeration, and diffusion at low concentrations. Environ. Sci. Technol. 2005, 39:9370-9376.
107. 2 particles in mice. Biol. Trace Elem. Res. 2009, 129:170-180.
108. Liu Z., Ren G., Zhang T., Yang Z. Action potential changes associated with the inhibitory effects on voltage-gated sodium current of hippocampal CA1 neurons by silver nanoparticles. Toxicology 2009, 264:179-184.
109. Liu C.H., Ren J.Q., You Z., Yang J., Liu C.M., Uppal R., Liu P.K. Noninvasive detection of neural progenitor cells in living brains by MRI. FASEB J. 2012, 26:1652-1662.
110. Liu Z., Zhang T., Ren G., Yang Z. Nano-Ag inhibiting action potential independent glutamatergic synaptic transmission but increasing excitability in rat CA1 pyramidal neurons. Nanotoxicology 2012, 6:414-423.
111. Locht L.J., Pedersen M.Ø., Markholt S., Bibby B.M., Larsen A., Penkowa M., Stoltenberg M., Rungby J. Metallic silver fragments cause massive tissue loss in the mouse brain. Basic Clin. Pharmacol. Toxicol. 2011, 109:1-10.
112. Lockman P.R., Koziara J.M., Mumper R.J., Allen D.D. Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J. Drug Target. 2004, 12:635-641.
113. Long T.C., Saleh N., Tilton R.D., Lowry G.V., Veronesi B. Titanium dioxide (P25) produces reactive oxygen species in immortalized brain microglia (BV2): implications for nanoparticle neurotoxicity. Environ. Sci. Technol. 2006, 40:4346-4352.
114. Lossinsky A.S., Vorbrodt A.W., Wisniewski H.M. Scanning and transmission electron microscopic studies of microvascular pathology in the osmotically impaired blood-brain barrier. J. Neurocytol. 1995, 24:795-806.
115. Lu W., Wan J., She Z., Jiang X. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. J. Control. Release 2007, 118:38-53.
116. Ma X., Wu Y., Jin S., Tian Y., Zhang X., Zhao Y., Yu L., Liang X.J. Gold nanoparticles induce autophagosome accumulation through size-dependent nanoparticle uptake and lysosome impairment. ACS Nano 2011, 5:8629-8639.
117. Marmorato P., Ceccone G., Gianoncelli A., Pascolo L., Ponti J., Rossi F., Salomé M., Kaulich B., Kiskinova M. Cellular distribution and degradation of cobalt ferrite nanoparticles in Balb/3T3 mouse fibroblasts. Toxicol. Lett. 2011, 207:128-136.
118. Martins S., Costa-Lima S., Carneiro T., Cordeiro-da-Silva A., Souto E.B., Ferreira D.C. Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway. Int. J. Pharm. 2012, 430:216-227.
119. Minami S.S., Sun B., Popat K., Kauppinen T., Pleiss M., Zhou Y., Ward M.E., Floreancig P., Mucke L., Desai T., Gan L. Selective targeting of microglia by quantum dots. J. Neuroinflamm. 2012, 24:9-22.
120. Mishra B., Patel B.B., Tiwari S. Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine 2010, 6:9-24.
121. Moberly A.H., Czarnecki L.A., Pottackal J., Rubinstein T., Turkel D.J., Kass M.D., McGann J.P. Intranasal exposure to manganese disrupts neurotransmitter release from glutamatergic synapses in the central nervous system in vivo. Neurotoxicology 2012, 33:996-1004.
122. Moghimi S.M., Andersen A.J., Hashemi S.H., Lettiero B., Ahmadvand D., Hunter A.C., Andresen T.L., Hamad I., Szebeni J. Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. J. Control. Release 2010, 146:175-181.
123. Moghimi S.M., Peer D., Langer R. Reshaping the future of nanopharmaceuticals: ad iudicium. ACS Nano 2011, 5:8454-8458.
124. Monopoli M.P., Åberg C., Salvati A., Dawson K.A. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 2012, 7:779-786.
125. Monopoli M.P., Walczyk D., Campbell A., Elia G., Lynch I., Bombelli F.B., Dawson K.A. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J. Am. Chem. Soc. 2011, 133:2525-2534.
126. Mu X., Li Z., Li X., Mishra S.R., Zhang B., Si Z., Yang L., Jiang W., Yan B. Characterization of protein clusters of diverse magnetic nanoparticles and their dynamic interactions with human cells. J. Phys. Chem. C 2009, 113:5390-5395.
127. Nagy Z., Peters H., Hüttner I. Endothelial surface charge: blood-brain barrier opening to horseradish peroxidase induced by the polycation protamin sulfate. Acta Neuropathol. 1981, Suppl. 7:7-9.
128. Oberdörster G., Oberdörster E., Oberdörster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect. 2005, 113:823-839.
129. Oberdörster G., Sharp Z., Atudorei V., Elder A., Gelein R., Kreyling W., Cox C. Translocation of inhaled ultrafine particles to the brain. Inhal. Toxicol. 2004, 16:437-445.
130. Oostingh G.J., Casals E., Italiani P., Colognato R., Stritzinger R., Ponti J., Pfaller T., Kohl Y., Ooms D., Favilli F., Leppens H., Lucchesi D., Rossi F., Nelissen I., Thielecke H., Puntes V.F., Duschl A., Boraschi D. Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects. Part. Fibre Toxicol. 2011, 8:8.
131. Oszlánczi G., Vezér T., Sárközi L., Horváth E., Kónya Z., Papp A. Functional neurotoxicity of Mn-containing nanoparticles in rats. Ecotoxicol. Environ. Safe. 2010, 73:2004-2009.
132. Pardridge W.M. Blood-brain barrier drug targeting: the future of brain drug development. Mol. Interv. 2003, 3:90-105.
133. Pardridge W.M. Drug delivery to the brain. J. Cereb. Blood Flow Metab. 1997, 17:713-731.
134. Pautler M., Brenner S. Nanomedicine: promises and challenges for the future of public health. Int. J. Nanomed. 2010, 5:803-809.
135. Petry K.G., Boiziau C., Dousset V., Brochet B. Magnetic resonance imaging of human brain macrophage infiltration. Neurotherapeutics 2007, 4:434-442.
136. Phalen R.F., Mendez L.B., Oldham M.J. New developments in aerosol dosimetry. Inhal. Toxicol. 2010, 2010(22):6-14.
137. Piao M.J., Kang K.A., Lee I.K., Kim H.S., Kim S., Choi J.Y., Choi J., Hyun J.W. Silver nanoparticles induce oxidative cell damage in human liver cells through inhibition of reduced glutathione and induction of mitochondria-involved apoptosis. Toxicol. Lett. 2011, 201:92-100.
138. Pinkernelle J., Calatayud P., Goya G.F., Fansa H., Keilhoff G. Magnetic nanoparticles in primary neural cell cultures are mainly taken up by microglia. BMC Neurosci. 2012, 22:13-32.
139. Powers C.M., Badireddy A.R., Ryde I.T., Seidler F.J., Slotkin T.A. Silver nanoparticles compromise neurodevelopment in PC12 cells: critical contributions of silver ion, particle size, coating, and composition. Environ. Health Perspect. 2011, 119:37-44.
140. Qi W.H., Wang M.P. Size and shape dependent melting temperature of metallic nanoparticles. Mater. Chem. Phys. 2004, 88:280-284.
141. Qiao R., Jia Q., Hüwel S., Xia R., Liu T., Gao F., Galla H.J., Gao M. Receptor-mediated delivery of magnetic nanoparticles across the blood-brain barrier. ACS Nano 2012, 6:3304-3310.
142. Radcliffe P.M., Olabisi A.O., Wagner D.J., Leavens T., Wong B.A., Struve M.F., Chapman G.D., Wilfong E.R., Dorman D.C. Acute sodium tungstate inhalation is associated with minimal olfactory transport of tungsten (188W) to the rat brain. Neurotoxicology 2009, 30:445-450.
143. Raghnaill M.N., Bramini M., Ye D., Couraud P.O., Romero I.A., Weksler B., Aberg C., Salvati A., Lynch I., Dawson K.A. Paracrine signalling of inflammatory cytokines from an in vitro blood brain barrier model upon exposure to polymeric nanoparticles. Analyst 2014, 139:923-930.
144. Ragnaill M.N., Brown M., Ye D., Bramini M., Callanan S., Lynch I., Dawson K.A. Internal benchmarking of a human blood-brain barrier cell model for screening of nanoparticle uptake and transcytosis. Eur. J. Pharm. Biopharm. 2011, 77:360-367.
145. Rahman M.F., Wang J., Patterson T.A., Saini U.T., Robinson B.L., Newport G.D., Murdock R.C., Schlager J.J., Hussain S.M., Ali S.F. Expression of genes related to oxidative stress in the mouse brain after exposure to silver-25 nanoparticles. Toxicol. Lett. 2009, 187:15-21.
146. Rajawat Y.S., Hilioti Z., Bossis I. Aging: central role for autophagy and the lysosomal degradative system. Ageing Res. Rev. 2009, 8:199-213.
147. Ramge P., Unger R.E., Oltrogge J.B., Zenker D., Begley D., Kreuter J., Von Briesen H. Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells. Eur. J. Neurosci. 2000, 12:1931-1940.
148. Rao D.B., Wong B.A., McManus B.E., McElveen A.M., James A.R., Dorman D.C. Inhaled iron, unlike manganese, is not transported to the rat brain via the olfactory pathway. Toxicol. Appl. Pharmacol. 2003, 193:116-126.
149. Re F. Inflammasome activation by pathogenic crystals and particles. The Inflammasomes. Book series: Progress in Inflammation Research 2011, 85-99. Springer Basel AG. I. Couillin, V. Pétrilli, F. Martinon (Eds.).
150. Rempe R., Cramer S., Hüwel S., Galla H.J. Transport of poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity. Biochem. Biophys. Res. Commun. 2011, 406:64-69.
151. Rong W., Ding W., Mädler L., Ruoff R.S., Friedlander S.K. Mechanical properties of nanoparticle chain aggregates by combined AFM and SEM: isolated aggregates and networks. Nano Lett. 2006, 6:2646-2655.
152. Sánchez-Danés A., Consiglio A., Richaud Y., Rodríguez-Pizà I., Dehay B., Edel M., Bové J., Memo M., Vila M., Raya A., Izpisua Belmonte J.C. Efficient generation of A9 midbrain dopaminergic neurons by lentiviral delivery of LMX1A in human embryonic stem cells and induced pluripotent stem cells. Hum. Gene Ther. 2012, 23:56-69.
153. Sánchez-Danés A., Richaud-Patin Y., Carballo-Carbajal I., Jiménez-Delgado S., Caig C., Mora S., Di Guglielmo C., Ezquerra M., Patel B., Giralt A., Canals J.M., Memo M., Alberch J., López-Barneo J., Vila M., Cuervo A.M., Tolosa E., Consiglio A., Raya A. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol. Med. 2012, 4:380-395.
154. Sarker D.K. Engineering of nanoemulsions for drug delivery. Curr. Drug Deliv. 2005, 2:297-310.
155. Sayes C.M., Marchione A.A., Reed K.L., Warheit D.B. Comparative pulmonary toxicity assessments of C60 water suspensions in rats: few differences in fullerene toxicity in vivo in contrast to in vitro profiles. Nano Lett. 2007, 7:2399-2406.
156. Schrand A.M., Rahman M.F., Hussain S.M., Schlager J.J., Smith D.A., Syed A.F. Metal-based nanoparticles and their toxicity assessment. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2010, 2:544-568.
157. Schroeder U., Sommerfeld P., Sabel B.A. Efficacy of oral dalargin-loaded nanoparticle delivery across the blood-brain barrier. Peptides 1998, 19:777-780.
158. Sekhon B.S. Food nanotechnology - an overview. Nanotechnol. Sci. Appl. 2010, 3:1-15.
159. Seo Y., Hong K.H., Kim S.H., Chang D., Lee K.H., Kim Y.D. Removal of bacterial pathogen from wastewater using Al filter with Ag-containing nanocomposite film by in situ dispersion involving polyol process. J. Hazard Mater. 2012, 227/228:469-473.
160. Sharma H.S., Sharma A. Nanoparticles aggravate heat stress induced cognitive deficits, blood-brain barrier disruption, edema formation and brain pathology. Prog. Brain Res. 2007, 162:245-273.
161. Sharma H.S., Ali S.F., Hussain S.M., Schlager J.J., Sharma A. Influence of engineered nanoparticles from metals on the blood-brain barrier permeability, cerebral blood flow, brain edema and neurotoxicity. An experimental study in the rat and mice using biochemical and morphological approaches. J. Nanosci. Nanotechnol. 2009, 9:5055-5072.
162. Sharma H.S. Nanoneuroscience and Nanoneuropharmacology Book series: progress in brain research 2009, vol. 180:1-350. Elsevier, The Netherlands.
163. Sharma H.S. Blood-central nervous system barriers: the gateway to neurodegeneration, neuroprotection and neuroregeneration. Handbook of Neurochemistry and Molecular Neurobiology: Brain and Spinal Cord Trauma 2009, 363-457. Springer, Berlin/Heidelberg/New York. A. Lajtha, N. Banik, S.K. Ray (Eds.).
164. Sharma H.S., Hussain S., Schlager J., Ali S.F., Sharma A. Influence of nanoparticles on blood-brain barrier permeability and brain edema formation in rats. Acta Neurochir. Suppl. 2010, 106:359-364.
165. Sharma H.S., Sharma A. Neurotoxicity of engineered nanoparticles from metals. CNS Neurol. Disord. Drug Targets 2012, 11:65-80.
166. Sharma H.S., Sharma A. New perspectives of nanoneuroprotection, nanoneuropharmacology and nanoneurotoxicity: modulatory role of amino acid neurotransmitters, stress, trauma, and co-morbidity factors in nanomedicine. Amino Acids 2013, 45:1055-1071.
167. Sharma V., Anderson D., Dhawan A. Zinc oxide nanoparticles induce oxidative DNA damage and ROS-triggered mitochondria mediated apoptosis in human liver cells (HepG2). Apoptosis 2012, 17:852-870.
168. Shemetov A.A., Nabiev I., Sukhanova A. Molecular interaction of proteins and peptides with nanoparticles. ACS Nano 2012, 6:4585-4602.
169. Shin J.A., Lee E.J., Seo S.M., Kim H.S., Kang J.L., Park E.M. Nanosized titanium dioxide enhanced inflammatory responses in the septic brain of mouse. Neuroscience 2010, 165:445-454.
170. Shipway A.N., Katz E., Willner I. Nanoparticle arrays on surfaces for electronic, optical, and sensor applications. ChemPhysChem 2000, 1:18-52.
171. Silva A.C., Oliveira T.R., Mamani J.B., Malheiros S.M., Malavolta L., Pavon L.F., Sibov T.T., Amaro E., Tannús A., Vidoto E.L., Martins M.J., Santos R.S., Gamarra L.F. Application of hyperthermia induced by superparamagnetic iron oxide nanoparticles in glioma treatment. Int. J. Nanomed. 2011, 6:591-603.
172. Sulzer D., Mosharov E., Talloczy Z., Zucca F.A., Simon J.D., Zecca L. Neuronal pigmented autophagic vacuoles: lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and disease. J. Neurochem. 2008, 106:24-36.
173. Sun J., Simon S.L. The melting behaviour of aluminium nanoparticles. Thermochim. Acta 2007, 463:32-40.
174. Tang J., Xiong L., Zhou G., Wang S., Wang J., Liu L., Li J., Yuan F., Lu S., Wan Z., Chou L., Xi T. Silver nanoparticles crossing through and distribution in the blood-brain barrier in vitro. J. Nanosci. Nanotechnol. 2010, 10:6313-6317.
175. Tang J., Xiong L., Wang S., Wang J., Liu L., Li J., Yuan F., Xi T. Distribution, translocation and accumulation of silver nanoparticles in rats. J. Nanosci. Nanotechnol. 2009, 9:4924-4932.
176. Teodoro J.S., Simões A.M., Duarte F.V., Rolo A.P., Murdoch R.C., Hussain S.M., Palmeira C.M. Assessment of the toxicity of silver nanoparticles in vitro: a mitochondrial perspective. Toxicol. In Vitro 2011, 25:664-670.
177. Tomalia D.A., Fréchet J.M.J. Discovery of dendrimers and dendritic polymers: a brief historical perspective. J. Polym. Sci. A: Polym. Chem. 2002, 40:2719-2728.
178. Torchilin V.P. Passive and active drug targeting: drug delivery to tumors as an example. Handb. Exp. Pharmacol. 2010, 197:3-53.
179. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 2007, 24:1-16.
180. Trickler W.J., Lantz S.M., Murdock R.C., Schrand A.M., Robinson B.L., Newport G.D., Schlager J.J., Oldenburg S.J., Paule M.G., Slikker W., Hussain S.M., Ali S.F. Silver nanoparticle induced blood-brain barrier inflammation and increased permeability in primary rat brain microvessel endothelial cells. Toxicol. Sci. 2010, 118:160-170.
181. Vallhov H., Qin J., Johansson S.M., Ahlborg N., Muhammed M.A., Scheynius A., Gabrielsson S. The importance of an endotoxin-free environment during the production of nanoparticles used in medical applications. Nano Lett. 2006, 6:1682-1686.
182. Vauthier C., Labarre D., Ponchel G. Design aspects of poly(alkylcyanoacrylate) nanoparticles for drug delivery. J. Drug Target. 2007, 15:641-663.
183. Vinogradov S.V., Bronich T.K., Kabanov A.V. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv. Drug Deliv. Rev. 2002, 54:135-147.
184. Vyas T.K., Shahiwala A., Amiji M.M. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. Int. J. Pharm. 2008, 347:93-101.
185. Xie H., Zhu Y., Jiang W., Zhou Q., Yang H., Gu N., Zhang Y., Xu H., Xu H., Yang X. Lactoferrin-conjugated superparamagnetic iron oxide nanoparticles as a specific MRI contrast agent for detection of brain glioma in vivo. Biomaterials 2011, 32:495-502.
186. Xu F., Piett C., Farkas S., Qazzaz M., Syed N.I. Silver nanoparticles (AgNPs) cause degeneration of cytoskeleton and disrupt synaptic machinery of cultured cortical neurons. Mol. Brain 2013, 6:29.
187. Xu L.J., Zhao J.X., Zhang T., Ren G.G., Yang Z. In vitro study on influence of nano particles of CuO on CA1 pyramidal neurons of rat hippocampus potassium currents. Environ. Toxicol. 2009, 24:211-217.
188. 3 particles into the brain: micro-distribution, chemical states, and histopathological observation. Biol. Trace Elem. Res. 2007, 118:233-243.
189. Wang F., Yu L., Monopoli M.P., Sandin P., Mahon E., Salvati A., Dawson K.A. The biomolecular corona is retained during nanoparticle uptake and protects cells from the damage induced by cationic nanoparticles until degraded in the lysosomes. Nanomed.: Nanotechnol. Biol. Med. 2013, 9:1159-1168.
190. Wang J., Liu Y., Jiao F., Lao F., Li W., Gu Y., Li Y., Ge C., Zhou G., Li B., Zhao Y., Chai Z., Chen C. Time-dependent translocation and potential impairment on central nervous system by intranasally instilled TiO(2) nanoparticles. Toxicology 2008, 254:82-90.
191. Wang J., Chen C., Liu Y., Jiao F., Li W., Lao F., Li Y., Li B., Ge C., Zhou G., Gao Y., Zhao Y., Chai Z. Potential neurological lesion after nasal instillation of TiO(2) nanoparticles in the anatase and rutile crystal phases. Toxicol. Lett. 2008, 183:72-80.
192. Wang J., Rahman M.F., Duhart H.M., Newport G.D., Patterson T.A., Murdock R.C., Hussain S.M., Schlager J.J., Ali S.F. Expression changes of dopaminergic system-related genes in PC12 cells induced by manganese, silver, or copper nanoparticles. Neurotoxicology 2009, 30:926-933.
193. Wang Y., Wang B., Zhu M.T., Li M., Wang H.J., Wang M., Ouyang H., Chai Z.F., Feng W.Y., Zhao Y.L. Microglial activation, recruitment and phagocytosis as linked phenomena in ferric oxide nanoparticle exposure. Toxicol. Lett. 2011, 205:26-37.
194. Wei L., Tang J., Zhang Z., Chen Y., Zhou G., Xi T. Investigation of the cytotoxicity mechanism of silver nanoparticles in vitro. Biomed. Mater. 2010, 5:044103.
195. Weiszhár Z., Czúcz J., Révész C., Rosivall L., Szebeni J., Rozsnyay Z. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. Eur. J. Pharm. Sci. 2012, 45:492-498.
196. Writer M.J., Kyrtatos P.G., Bienemann A.S., Pugh J.A., Lowe A.S., Villegas-Llerena C., Kenny G.D., White E.A., Gill S.S., McLeod C.W., Lythgoe M.F., Hart S.L. Lipid peptide nanocomplexes for gene delivery and magnetic resonance imaging in the brain. J. Control. Release 2012, 162:340-348.
197. Wu J., Wang C., Sun J., Xue Y. Neurotoxicity of silica nanoparticles: brain localization and dopaminergic neurons damage pathways. ACS Nano 2011, 5:4476-4489.
198. Wu H.Y., Chung M.C., Wang C.C., Huang C.H., Liang H.J., Jan T.R. Iron oxide nanoparticles suppress the production of IL-1beta via the secretory lysosomal pathway in murine microglial cells. Part. Fibre Toxicol. 2013, 10:46.
199. Yang H. Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm. Res. 2010, 27:1759-1771.
200. Zecca L., Bellei C., Costi P., Albertini A., Monzani E., Casella L., Gallorini M., Bergamaschi L., Moscatelli A., Turro N.J., Eisner M., Crippa P.R., Ito S., Wakamatsu K., Bush W.D., Ward W.C., Simon J.D., Zucca F.A. New melanic pigments in the human brain that accumulate in aging and block environmental toxic metals. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:17567-17572.
201. Zecca L., Wilms H., Geick S., Claasen J.H., Brandenburg L.O., Holzknecht C., Panizza M.L., Zucca F.A., Deuschl G., Sievers J., Lucius R. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease. Acta Neuropathol. 2008, 116:47-55.
202. Zensi A., Begley D., Pontikis C., Legros C., Mihoreanu L., Wagner S., Büchel C., von Briesen H., Kreuter J. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J. Control. Release 2009, 137:78-86.
203. Zhang W., Phillips K., Wielgus A.R., Liu J., Albertini A., Zucca F.A., Faust R., Qian S.Y., Miller D.S., Chignell C.F., Wilson B., Jackson-Lewis V., Przedborski S., Joset D., Loike J., Hong J.S., Sulzer D., Zecca L. Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox. Res. 2011, 19:63-72.
204. Zhao J., Xu L., Zhang T., Ren G., Yang Z. Influences of nanoparticle zinc oxide on acutely isolated rat hippocampal CA3 pyramidal neurons. Neurotoxicology 2009, 30:220-230.
205. Zucca F.A., Basso E., Cupaioli F.A., Ferrari E., Sulzer D., Casella L., Zecca L. Neuromelanin of the human substantia nigra: an update. Neurotox. Res. 2014, 25:13-23.